Novartis AG $NVS Holdings Reduced by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC cut its stake in Novartis AG (NYSE:NVS) by 16.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 98,416 shares of the company’s stock after selling 19,603 shares during the period. Exencial Wealth Advisors LLC’s holdings in Novartis were worth $11,909,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. WPG Advisers LLC acquired a new stake in shares of Novartis during the first quarter worth $25,000. Tsfg LLC boosted its position in shares of Novartis by 366.0% in the 1st quarter. Tsfg LLC now owns 233 shares of the company’s stock valued at $26,000 after purchasing an additional 183 shares during the period. GFG Capital LLC acquired a new position in shares of Novartis in the 2nd quarter valued at $26,000. Barrett & Company Inc. acquired a new position in shares of Novartis in the 2nd quarter valued at $31,000. Finally, MCF Advisors LLC boosted its position in shares of Novartis by 66.0% in the 2nd quarter. MCF Advisors LLC now owns 264 shares of the company’s stock valued at $32,000 after purchasing an additional 105 shares during the period. 13.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NVS shares. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target for the company in a research report on Friday, August 8th. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Novartis in a research report on Thursday, August 21st. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 target price (down previously from $119.00) on shares of Novartis in a research report on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $120.33.

Novartis Stock Down 0.4%

NVS stock opened at $131.29 on Wednesday. Novartis AG has a 12-month low of $96.06 and a 12-month high of $133.55. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 0.53. The company has a market cap of $277.34 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 1.84 and a beta of 0.64. The company has a 50 day moving average of $127.04 and a two-hundred day moving average of $118.89.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.